MONTPELLIER, FRANCE — Hearing therapeutics company Cilcare has announced two exclusive licensing agreements with pharmaceutical company Sanofi covering investigational drug candidates targeting different biological mechanisms associated with hearing loss....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — these are early-stage licensing deals for investigational compounds with no human efficacy or safety data yet reported.
Major pharmaceutical investment in hearing loss drug pipelines signals growing industry interest in inner-ear therapeutics, which could eventually offer audiologists treatment options beyond amplification.
- 01Cilcare secured two exclusive licensing agreements with Sanofi for investigational hearing loss drug candidates.
- 02The two compounds target distinct biological mechanisms associated with hearing loss.
- 03Both candidates are pre-clinical or early-stage; no human trial results are disclosed.
- 04The deal expands Cilcare's drug pipeline rather than bringing a product to market.
- 05This reflects broader pharmaceutical industry momentum toward pharmacological hearing loss treatments.
Cilcare obtained two exclusive licenses from Sanofi covering drug candidates targeting distinct biological mechanisms associated with hearing loss.
press releasesupportedThe licensed drug candidates target distinct biological mechanisms associated with hearing loss.
press releaseunclear